AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32812840
Drug: Stuttering treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stuttering treatment integrated with EBPS for children with eADHD (eADHDintegrated)
Trial: 35373603
Drug: Topical Tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical Tranexamic Acid (TA)
Trial: 33370517
Drug: Nondamaging retinal
RxNorm normalized name: retinaldehyde
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nondamaging retinal laser therapy (NRT)
Trial: 35982464
Drug: CC-99677
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-99677
Trial: 32183608
Drug: Iodine-containing prenatal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodine-containing prenatal multiple micronutrient (MMN) supplement (300 μg of iodine)
Trial: 32183608
Drug: Iron and
RxNorm normalized name: beef,iron and wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron and folic acid (FeFol) supplement
Trial: 35191982
Drug: Ticagrelor in
RxNorm normalized name: Product containing ticagrelor in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor in preadmission aspirin and/or clopidogrel group
Trial: 35191982
Drug: Prasugrel in
RxNorm normalized name: Product containing prasugrel in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel in preadmission aspirin and/or clopidogrel group
Trial: 35191982
Drug: Ticagrelor in
RxNorm normalized name: Product containing ticagrelor in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor in no preadmission aspirin or clopidogrel group
Trial: 35191982
Drug: Prasugrel in
RxNorm normalized name: Product containing prasugrel in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel in no preadmission aspirin or clopidogrel group
Trial: 33370510
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg intravenous ketorolac
Trial: 33370510
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg intravenous ketorolac
Trial: 33370510
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg intravenous ketorolac
Trial: 33370510
Drug: Rescue analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue analgesic (0.1 mg/kg intravenous morphine sulfate)
Trial: 33430891
Drug: Methylprednisolone (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (120 mg IV once daily on days 1, 2, and 3) plus standard of care
Trial: 33430891
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% saline IV once daily on days 1, 2, and 3) plus standard of care
Trial: 34967844
Drug: GnRHa (3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRHa (3.6 mg goserelin or 3.75 mg leuprorelin injected subcutaneously once every 28 days)
Trial: 34967844
Drug: Control (chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (chemotherapy without GnRHa)
Trial: 33588478
Drug: Xylazine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylazine (0.1 mg/kg)
Trial: 33588478
Drug: Detomidine (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detomidine (0.03 mg/kg)
Trial: 32480409
Drug: Goserelin acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin acetate plus 0 grams of testosterone gel (placebo)
Trial: 32480409
Drug: Goserelin acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin acetate plus 1.25 grams of testosterone gel
Trial: 32480409
Drug: Goserelin acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin acetate plus 2.5 grams of testosterone gel
Trial: 32480409
Drug: Goserelin acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin acetate plus 5 grams of testosterone gel
Trial: 32480409
Drug: Goserelin acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin acetate plus 10 grams of testosterone gel
Trial: 38485313
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL 0.5% bupivacaine
Trial: 35524405
Drug: Eptinezumab (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eptinezumab (100 mg and 300 mg doses)
Trial: 33187890
Drug: Extended-release tolterodine
RxNorm normalized name: tolterodine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release tolterodine
Trial: 33487155
Drug: Rivaroxaban 15
RxNorm normalized name: rivaroxaban 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 15 mg/day (n=73)
Trial: 33487155
Drug: Warfarin (n=36)
RxNorm normalized name: (-)-Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin (n=36)
Trial: 33084584
Drug: Baseline daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline daily steps
Trial: 36654481
Drug: Concentrated pomegranate
RxNorm normalized name: Pomegranate
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrated pomegranate juice (PJ) 45 ml/day
Trial: 33472675
Drug: C1 esterase/kallikrein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C1 esterase/kallikrein inhibitor 20 U/kg intravenously on day 1 and day 4 plus standard care
Trial: 33472675
Drug: Icatibant 30
RxNorm normalized name: icatibant 30 MG in 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icatibant 30 mg subcutaneously, three doses/day for 4 days plus standard care
Trial: 36156313
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard chemo-mechanical treatment)
Trial: 33357677
Drug: Daily feed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily feed intake (DFI)
Trial: 34808036
Drug: 3.7 g
RxNorm normalized name: Toxi-Sorb 3.7 GM Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.7 g day-1 n-3 fatty acids (fish oil)
Trial: 35396307
Drug: Low-dose naltrexone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose naltrexone (LDN) 4.5 mg once daily for 12 weeks
Trial: 34120223
Drug: T-DM1 3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-DM1 3.6 mg/kg IV every 3 weeks × 17
Trial: 34120223
Drug: Paclitaxel (T)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel (T) 80 mg/m2 with trastuzumab (H) IV qw × 12 (4 mg/kg load → 2 mg/kg), followed by H (6 mg/kg IV q3w × 13)
Trial: 32538009
Drug: Oral analgesics
RxNorm normalized name: ANALGESIC CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral analgesics (bucinnazine hydrochloride and oxycodone hydrochloride)
Trial: 33908343
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioral therapy for insomnia (ICBT-I)
Trial: 34490711
Drug: Rhythmic eye
RxNorm normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhythmic eye movements during virtual reality exposure therapy (VRET)
Trial: 32294883
Drug: Apple Polyphenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apple Polyphenol (AP) 300 mg/day
Trial: 32294883
Drug: Apple Polyphenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apple Polyphenol (AP) 600 mg/day
Trial: 35581106
Drug: Cardamom inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardamom inhalation therapy
Trial: 34288956
Drug: Substance use
RxNorm normalized name: reSET Substance Use Disorder Therapy Software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substance use (smoking, drug use, alcohol consumption)
Trial: 33580692
Drug: Lactononadecapeptide (LNDP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactononadecapeptide (LNDP) tablets
Trial: 39188412
Drug: Traction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traction therapy (TT)
Trial: 33390422
Drug: Post-meal fast-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-meal fast-acting insulin aspart
Trial: 32926418
Drug: 450 mg
RxNorm normalized name: aspirin 450 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg Valganciclovir (VGCV) daily
Trial: 32926418
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg Valganciclovir (VGCV) daily
Trial: 32926418
Drug: Sampling strategies
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sampling strategies of plasma concentrations at 0 and 2 hours and 0, 2, and 4 hours after VGCV administration
Trial: 34454788
Drug: Rotavirus vaccine
RxNorm normalized name: rotavirus vaccine
DrugBank: Rotavirus vaccine (DB10276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotavirus vaccine (RV) with routine EPI vaccines
Trial: 33207993
Drug: Partial Enteral
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial Enteral Nutrition (PEN) - casein-based formula for 12 months providing 25% of estimated daily energy requirements
Trial: 33196153
Drug: Subcutaneous evinacumab
RxNorm normalized name: Evinacumab
DrugBank: Evinacumab (DB15354)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subcutaneous evinacumab 450 mg weekly
Trial: 33196153
Drug: Subcutaneous evinacumab
RxNorm normalized name: Evinacumab
DrugBank: Evinacumab (DB15354)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subcutaneous evinacumab 300 mg weekly
Trial: 33196153
Drug: Subcutaneous evinacumab
RxNorm normalized name: Evinacumab
DrugBank: Evinacumab (DB15354)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subcutaneous evinacumab 300 mg every 2 weeks
Trial: 33196153
Drug: Intravenous evinacumab
RxNorm normalized name: Evinacumab
DrugBank: Evinacumab (DB15354)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous evinacumab 15 mg/kg every 4 weeks
Trial: 33196153
Drug: Intravenous evinacumab
RxNorm normalized name: Evinacumab
DrugBank: Evinacumab (DB15354)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous evinacumab 5 mg/kg every 4 weeks
Trial: 32883723
Drug: Online cognitive-behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online cognitive-behavioural therapy (CBT)
Trial: 34981621
Drug: Biocon's Insulin‐R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biocon's Insulin‐R
Trial: 35190972
Drug: QLHER2 (test)
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QLHER2 (test) at single doses escalating from 0.2 to 6 mg/kg
Trial: 35190972
Drug: Herceptin (reference)
RxNorm normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Herceptin (reference) at 4 mg/kg
Trial: 33137340
Drug: EOS789 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EOS789 50 mg
Trial: 33137340
Drug: EOS789 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EOS789 100 mg
Trial: 33137340
Drug: EOS789 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EOS789 100 mg plus 1600 mg sevelamer
Trial: 35565859
Drug: Amorphous Calcium
RxNorm normalized name: Casein Phosphopeptide-Amorphous Calcium Phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amorphous Calcium Carbonate (ACC) supplementation (2000 mg per day)
Trial: 32835498
Drug: 47 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 47 g/kg sunflower meal (SFM)
Trial: 32835498
Drug: 97 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 97 g/kg sunflower meal (SFM)
Trial: 32835498
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (corn and soybean meal, 30 g/kg crude fibre)
Trial: 35426485
Drug: Newly developed
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newly developed biological therapies
Trial: 35426485
Drug: Traditional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional therapy with first- and second-line drugs
Trial: 32758672
Drug: Role-playing twice
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Role-playing twice
Trial: 33184931
Drug: Atrasentan 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrasentan 0.75 mg for six weeks
Trial: 34127610
Drug: Flywheel training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flywheel training (twice weekly squat and calf raise exercises for 6 weeks)
Trial: 36480811
Drug: zanubrutinib (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: zanubrutinib (80 mg BID) with moderate CYP3A inhibitors fluconazole and diltiazem
Trial: 36480811
Drug: zanubrutinib (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: zanubrutinib (80 mg QD) with strong CYP3A inhibitor voriconazole
Trial: 36480811
Drug: zanubrutinib (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: zanubrutinib (320 mg QD)
Trial: 33661781
Drug: Oral carbohydrate
RxNorm normalized name: omega-3 carboxylic acids Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral carbohydrate (group OC)
Trial: 33661781
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo (group OP)
Trial: 35078853
Drug: 3-weekly durvalumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-weekly durvalumab 1500 mg plus 3-weekly doublet chemotherapy (cisplatin 75 mg/m2 or carboplatin, AUC 5 and pemetrexed 500 mg/m2) for 4-6 cycles, followed by 4-weekly durvalumab 1500 mg until disease progression, unacceptable toxicity or patient withdrawal
Trial: 35078853
Drug: Doublet chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doublet chemotherapy alone for 4-6 cycles, followed by observation
Trial: 33238010
Drug: Digital rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital rehabilitation program (application) along with traditional physical therapy (PT)
Trial: 33238010
Drug: Traditional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional physical therapy (PT)
Trial: 39698346
Drug: SGLT2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT2 inhibitors (SGLT2i)
Trial: 33271428
Drug: GLP1 receptor
RxNorm normalized name: XTEN-GLP1
DrugBank: Vurolenatide (DB18440)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP1 receptor agonists (GLP1RA)
Trial: 35149638
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy support (counseling, relaxation, mindfulness-based exercises)
Trial: 33810808
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml pomegranate juice and standard of care hospital treatment for COVID-19
Trial: 33810808
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo containing 500 ml of red water and standard of care hospital treatment for COVID-19
Trial: 34527079
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplements (ONSs) with a high‐protein–high‐calorie mixture containing immunonutrients (Impact)
Trial: 32293119
Drug: Intraarticular injection
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraarticular injection of trans-capsaicin
Trial: 36364934
Drug: HMB +
RxNorm normalized name: Hydroxymethylbutyrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB + D (3 g Calcium HMB + 2000 IU D per day)
Trial: 33982872
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 5 mg tablet daily for 12 weeks
Trial: 33982872
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 5 mg tablet
Trial: 32860406
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of bone marrow-derived mononuclear cells (BM-MNCs) 2-8 days after PPCI
Trial: 32860406
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of bone marrow-derived mononuclear cells (BM-MNCs)
Trial: 35198913
Drug: Reactive focal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reactive focal mass drug administration (rfMDA)
Trial: 33916192
Drug: Probiotic preparation
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic preparation comprising Lactobacillus rhamnosus ŁOCK 0900, Lactobacillus rhamnosus ŁOCK 0908, and Lactobacillus casei ŁOCK 0918 at a daily dose of 10^9 bacteria for three months.
Trial: 32173916
Drug: guselkumab 100
RxNorm normalized name: guselkumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guselkumab 100 or 200 mg at weeks 0, 4, 12 and every 8 weeks
Trial: 32173916
Drug: guselkumab 100
RxNorm normalized name: guselkumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guselkumab 100 or 200 mg
Trial: 35675561
Drug: 2 Mini
RxNorm normalized name: CLN2 RDNA CONSTRUCT DISRUPTING EXON 6 OF CLN2 GENE IN YUCATAN MINIATURE SWINE 1 [arb'U] in 1 [arb'U] NOT APPLICABLE NOT APPLICABLE [ExeGen CLN2 miniswine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 Mini Dental Implants (2MDI)
Trial: 35675561
Drug: 4 Mini
RxNorm normalized name: wheat germ oil 14 minim ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 Mini Dental Implants (4MDI)
Trial: 35675561
Drug: 2 Conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 Conventional Dental Implants (2CDI)
Trial: 35927547
Drug: Untailored information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Untailored information derived from the Vaccine Information Sheet (VIS)
Trial: 33400099
Drug: Enoxaparin 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 0.5 mg/kg daily (weight-based dosing)
Trial: 35213415
Drug: TMB-L +
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMB-L + BRAF WT
Trial: 35213415
Drug: TMB-L +
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMB-L + NRAS mut
Trial: 35213415
Drug: TMB-L tumors
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMB-L tumors
Trial: 34072223
Drug: One-off application
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-off application of a structured 5-step implicit process to simplify medication regimens.
Trial: 34072223
Drug: One-off implicit
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-off implicit medication simplification intervention.
Trial: 33035492
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (TXA) 20 mg/kg
Trial: 33035492
Drug: Intravenous normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous normal saline (0.09%)
Trial: 34181143
Drug: 1-mg melatonin
RxNorm normalized name: melatonin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-mg melatonin
Trial: 34181143
Drug: 4-mg melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-mg melatonin
Trial: 34859852
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus Vitamin D supplementation
Trial: 34859852
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment without Vitamin D
Trial: 38874618
Drug: Neither therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neither therapy
Trial: 32864597
Drug: Sensor-Augmented Pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensor-Augmented Pump Therapy (SAP)
Trial: 36307274
Drug: Lifestyle plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle plus medication therapy management
Trial: 35587681
Drug: Nitrous oxide/oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrous oxide/oxygen inhalation
Trial: 33001381
Drug: Spatz3® adjustable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spatz3® adjustable intragastric balloon (IGB) with upward adjustment (250 mL greater volume)
Trial: 33001381
Drug: Spatz3® adjustable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spatz3® adjustable intragastric balloon (IGB) with constant volume (600 mL)
Trial: 32562076
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) at 200-mW, 6-J, continuous-wave mode for 30 seconds
Trial: 35988206
Drug: Papaverine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papaverine infusion through aortic root